Le Lézard
Classified in: Health
Subject: FDA

ChiRhoStim® (Human Secretin for Injection) FDA approved labeling update and 5-year shelf life approval

BURTONSVILLE, Md., July 25, 2017 /PRNewswire/ -- ChiRhoClin, Inc. is pleased to notify the medical community that ChiRhoStim® (Human Secretin for Injection) has received FDA approval, updating its package insert. There are two significant changes to the package insert.  The first change eliminates the need to inject a test dose prior to administering ChiRhoStim®.  The second significant change is the removal of the contraindication section.  The benefit for patients experiencing an acute pancreatitis episode is that they can be administered ChiRhoStim® for pancreatic evaluation. These two changes to the package labeling may shorten procedure time and patient treatment.  In addition, an extended 5-year shelf life of ChiRhoStim® was approved. This shelf life extension of the product stability will provide a steady stream of Secretin for the future.

ChiRhoStim® is an orphan drug product that aids in the diagnoses of pancreatic cancer and pancreatic exocrine dysfunction.  ChiRhoStim® is approved for pancreatic function testing, facilitating cannulation during ERCP, and Gastrinoma testing.  In addition, secretions of the pancreatic fluid after secretin stimulation can be used in situ for imaging modalities such as MRCP, CT, and EUS.

Skip Purich, C.O.O., said "These improvements to our product shelf life and updated labeling will assist the medical community in shortening Gastroenterology and Radiology procedure times.  As well as not delaying diagnostic testing such as secretin stimulated MRCP (SMRCP) or function testing while a patient is suffering from acute pancreatitis."        

ChiRhoClin, Inc., a Maryland based family run corporation founded in 1991 by Dr. Edward D. Purich, is a research and development oriented pharmaceutical company focused on developing orphan drug products for the gastrointestinal and radiological community.  Our emphasis is to develop orphan drug products that will diagnose and treat pancreatic gastrointestinal diseases and encourage research in the pancreatic area through our small pancreatic grant program.

If you would like more information on ChiRhoStim® (Human Secretin for Injection), please visit www.ChiRhoStim.com or call 1-877-272-4888. 


SOURCE ChiRhoClin, Inc.

These press releases may also interest you

at 16:03
Emblem Corp. ("Emblem" or the "Corporation") is pleased to announce that it has selected No Fixed Address ("NFA") as its agency of record, following a Request for Proposal process that included five agencies. Through the partnership, NFA and Emblem...

at 16:01
Proteostasis Therapeutics, Inc. , a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced...

at 16:01
Arena Pharmaceuticals, Inc. , today announced positive topline Phase 2 results from the OASIS trial for etrasimod, an investigational, once-daily, orally administered, selective sphingosine 1-phosphate (S1P) receptor modulator in development for the...

at 16:00
Griffin-American Healthcare REIT III, Inc. today announced operating results for the company's fourth quarter and year ended Dec. 31, 2017. "Griffin-American Healthcare REIT III acquired its first real estate asset in...

at 16:00
HLS Therapeutics Inc. today announced that it will release its fourth quarter 2017 financial results by press release on Thursday, March 29, 2018, prior to market open. The Company will subsequently hold a conference call that same day, Thursday,...

at 15:47
New England Cryogenic Center (NECC), a long-term cryogenic storage facility, has worked with the medical community and private clients to plan and preserve their fertility goals, since 1971.  The company has expertise in cryogenic storage and they...

News published on 25 july 2017 at 10:49 and distributed by: